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treatment in active rheumatoid arthritis: a
post hoc analysis from the SWEFOT trial
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Abstract
Background: The identification of biomarkers that predict optimal and individual choices of treatment for
patients with rheumatoid arthritis gains increasing attention. The purpose of this study was to investigate if the
proto-oncogene survivin might aid in treatment decisions in early rheumatoid arthritis.
Methods: Serum survivin levels were measured in 302 patients who completed the Swedish pharmacotherapy
(SWEFOT) trial at baseline, 3, 12, and 24 months. Survivin levels > 0.45 ng/mL were considered positive. Based on
the survivin status, core set outcomes measuring disease activity, functional disability, as well as global health and
pain were evaluated after methotrexate (MTX) monotherapy at 3 months, and at 12 and 24 months of follow-up.
Treatment of non-responders was randomly intensified with either a combination of disease-modifying antirheumatic
drugs (triple therapy: MTX, sulfasalazine, and hydroxychloroquine) or by adding antibodies against tumor necrosis
factor (anti-TNF).
Results: Antirheumatic treatment resulted in an overall decrease of serum survivin levels. Survivin-positive patients at
baseline who initially responded to MTX had a higher risk of disease re-activation (OR 3.21 (95 % CI 1.12–9.24),
P = 0.032) and failed to improve in their functional disability (P = 0.018) if having continued on MTX monotherapy
compared to survivin-negative patients. Ever-smokers who were survivin-positive were less likely to respond to MTX
than those who were survivin-negative (OR 1.91 (1.01–3.62), P = 0.045). In survivin-positive patients, triple therapy led to
better improvements in disease activity than did MTX + anti-TNF. At 24 months, survivin-positive patients randomized
to anti-TNF had a higher risk of active disease than those randomized to triple therapy (OR 3.15 (1.09–9.10), P = 0.037).
Discussion: We demonstrate for the first time that survivin is a valuable serologic marker that can distinguish drug-
specific clinical responses in early rheumatoid arthritis through the pragmatic clinical setting of the care-based SWEFOT
trial. Although treatment response cannot solely be attributable to survivin status, per protocol sensitivity analyses
confirmed the superior effect of triple therapy on survivin-positive patients.
Conclusions: Survivin-positive patients have poor outcomes if treated with MTX monotherapy. A decrease of survivin
levels during treatment is associated with better clinical responses. For survivin-positive patients who fail MTX, triple
therapy is associated with better outcomes than anti-TNF therapy.
Trial registration: WHO database at the Karolinska University Hospital: CT20080004; ClinicalTrials.gov: NCT00764725,
registered 1 October 2008.
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Background
Despite advances in antirheumatic treatment, rheuma-
toid arthritis (RA) continues to be associated with a sig-
nificant disease burden due to reduced quality of life [1],
functional disability [2], and an enhanced prevalence of
comorbidities [3, 4]. Marked individual heterogeneity
with respect to specific genetic and environmental load,
autoantibody production, and cellular, cytokine and gene
expression profiles of the inflamed synovia strongly sug-
gests that a more personalized choice of antirheumatic
treatment would yield considerably better results. A re-
quirement of biomarkers and algorithms capable of pre-
dicting treatment response and reducing unnecessary
expenses on the costs of inefficient medication has re-
cently been given high priority [5].
Methotrexate (MTX) is recommended as the top first-
line antirheumatic drug owing to its relatively high effi-
cacy and low rate of adverse events [6]. The combination
of MTX with glucocorticoids [7], other conventional an-
tirheumatic drugs [8], or with inhibitor of tumor necro-
sis factor (anti-TNF) [9, 10] could be more effective than
MTX monotherapy. For patients who fail initial MTX
therapy several reasonable options are available, including
the addition of sulfasalazine (SSZ) and hydroxychloro-
quine (HCQ) – the so-called ‘triple therapy’ (TT) – or the
addition of anti-TNF. The Swedish pharmacotherapy
(SWEFOT) trial was a standard care-based study [11],
where all patients initially received open-label MTX
monotherapy followed by randomized treatment with ei-
ther TT or with MTX in combination with anti-TNF (in
this case, infliximab) in the patients who failed to achieve
low disease activity on MTX. The trial showed that anti-
TNF was clinically superior to TT after 12 months, while
the difference between the treatment arms leveled-off
after 24 months [12]. Recent randomized controlled trials,
which compared the combination of conventional disease-
modifying drugs with biologic strategies, demonstrated
that both treatment options can be successful for some
patients [13, 14]. The results of randomized and observa-
tional studies [15, 16] indicated a substantial difference in
social care costs for these treatment alternatives. Thus, ex-
ponential increases in expenses urge reliable indicators
that would predict the optimal treatment choice for every
patient.
The proto-oncogene survivin is a biomarker of cancer
and may be found in most tumor tissues, such as lymph-
oma, colorectal carcinoma, breast cancer, small cell lung
adenocarcinoma, and others [17–20], where it predicts
prognosis and the potential for metastasis. Cellular func-
tions of survivin comprise inhibition of apoptosis in the
cytoplasmic and mitochondrial compartments by pre-
venting activation of caspases, and regulation of the cell
cycle progression in the nucleus by aiding formation of a
chromosomal passenger complex [21, 22]. In healthy
tissues, survivin expression is indispensable for cell re-
newal and differentiation, being consistently expressed
in thymocytes, bone marrow hematopoietic progenitors
and stem cells, cells of the colon epithelium, and vascu-
lar endothelial cells [23–25].
In RA, serum survivin has recently emerged as a
marker of the disease. It is over-expressed in the pre-
clinical phase of RA, and, together with antibodies to
citrullinated peptides, is predictive for development of
RA several years ahead of clinical symptoms [26]. Im-
portantly, in the pre-symptomatic stage of RA, survivin
was associated with the pattern of regulatory cytokines
(interleukin (IL)-12, IL-1, IL-9, granulocyte-macrophage
colony-stimulating factor, and IL-2) controlling the for-
mation of pathogenic T helper (Th) 1 and Th17 lympho-
cytes. Also, survivin has been recently connected to
carriage of the human leukocyte antigen (HLA) DRB1
genotype and smoking [27, 28], important keystones in
the pathogenesis of RA. Survivin is critical for the
process of antigen presentation – the breaking point of
immune responses in RA, being required for the expres-
sion of major histocompatibility complex class II mol-
ecule receptors on dendritic cells [29] and for the
formation of functional T cell receptors [30, 31]. Expres-
sion of survivin in B cells might be attributable to ad-
verse cell recognition in RA, since changes in survivin
expression after therapeutic B cell depletion was associ-
ated with a reduction of B cell numbers, serum levels of
rheumatoid factor (RF) and the activity of arthritis [32].
In observational study cohorts, survivin assists with the
early recognition of RA patients with poor prognosis,
being associated with progressive joint damage and a
low rate of treatment response [33–35]. The role of sur-
vivin as a clinical predictor of drug-specific treatment
response has not been investigated in RA. Therefore, the
design of the SWEFOT trial provided an opportunity for
the simultaneous evaluation of clinical outcomes of dif-
ferent antirheumatic treatment strategies with respect to
the survivin status of the patients. In this post hoc ana-
lysis we asked if high levels of survivin in serum identi-
fied RA patients with poor response to antirheumatic
treatment and worse clinical outcomes over time.
Methods
Study design
The SWEFOT trial is an open-label randomized study
comparing treatment strategies in patients with early RA
[12]. Patients from 15 rheumatology units in Sweden with
symptom duration < 1 year and previously not treated
with disease-modifying antirheumatic drugs were invited
to participate in this trial. At inclusion, 487 patients with
the 28-joint count disease activity score (DAS28) > 3.2
were enrolled in the trial between December 2002 and
2006 (Fig. 1). All patients were initially treated with
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methotrexate (MTX, 20 mg/week). Clinical assessment at
3 months distinguished patients with DAS28 ≤ 3.2 (MTX
responders) and DAS28 > 3.2 (MTX non-responders).
MTX responders continued treatment with MTX mono-
therapy, while MTX non-responders were randomized
to TT (MTX+ SSZ +HCQ) or to anti-TNF therapy
(MTX+ infliximab). Clinical assessment of the patients
was performed at baseline and thereafter at 3, 12, and
24 months using the DAS28 and other ‘core set’ out-
comes, including functional disability measured by the
Health Assessment Questionnaire (HAQ), pain perception
graded by visual analog scale (pain-VAS), and patient’s
global assessment of disease activity (PtGA-VAS). A total
of 302 patients completed the 24-month trial period by
intention-to-treat and were the subjects for this analysis.
The study protocol was approved by the regional ethical
committees of Sweden. The SWEFOT trial has registra-
tion identification CT20080004 at the World Health
Organization (WHO) database at the Karolinska Univer-
sity Hospital, Stockholm, and registration identification
NCT00764725 at ClinicalTrials.gov. At enrollment, all pa-
tients gave their written informed consent to participate
in the study.
Measurements of serum survivin levels
Blood samples were obtained at baseline before MTX
treatment, and at 3 months for all patients enrolled in
the SWEFOT trial. At 12 and 24 months, samples for
the MTX non-responders were available. Samples were
centrifuged and stored at −80 °C.
Serum survivin levels were measured using a matched-
antibody pair (rabbit anti-human survivin) by a sand-
wich enzyme-linked immunosorbent assay (DYC647,
R&D Systems, Minneapolis, MN, USA) [33, 36]. The de-
tection limit of the assay was 0.1 ng/mL. The cut-off
level of 0.45 ng/mL was set as previously reported [29],
and was used to distinguish between survivin-positive
(+) and survivin-negative (−) patients.
Statistical analysis
The statistical analyses were based on intention-to-treat,
last observation carried forward. Changes in survivin
status after 3 months of MTX treatment resulted in the
formation of four survivin groups: survivin-positive
(+/+); survivin-negative (−/−); survivin converting to
negative (+/−); and survivin converting to positive (−/+).
Fig. 1 Analysis profile. Serum levels of survivin were measured from samples of 302 patients who completed the 24-month follow-up of the
SWEFOT trial. Measurements at baseline resulted in the survivin-positive (> 0.45 ng/mL) and survivin-negative patient groups. Measurements at 3,
12, and 24 months identified patients who decreased or increased their serum survivin levels at any time point over 24 months. Four groups of
patients were formed and compared: patients positive for survivin (PP), or negative for survivin (NN) on all testing occasions; and patients survivin-
positive at baseline who converted negative (PN), or survivin-negative patients who converted positive (NP). After 3 months of methotrexate
(MTX) monotherapy, patients still with active disease were randomized to triple therapy (MTX + sulfasalazine (SSZ) + hydroxychloroquine (HCQ)) or
to anti-TNF (MTX + infliximab). *Patients with missing samples at 12 and 24 months (n = 15), who were not randomized (n = 2), or who changed
their survivin status on several occasions (n = 15) were excluded from analysis
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Patients who changed survivin more than once (n = 15)
were excluded from the analysis.
Utilizing IBM SPSS v.22.0, and OpenEpi.com [37],
nonparametric statistical comparisons were performed.
Data is presented as the median and interquartile range
(IQR) for continuous variables, and frequency (%) or
odds ratio (OR) (95 % confidence interval, CI) for pro-
portions. Mann–Whitney U tests and Wilcoxon signed-
rank tests were used to compare continuous variables,
whereas Pearson’s χ2 or Fisher’s exact tests were utilized
for proportions. For the comparison of more than two
groups, initial analysis was done by Kruskal–Wallis tests,
followed by pairwise post hoc analyses by Dunn-
Bonferroni correction. All tests were two-tailed and per-
formed at the 0.05 level of significance.
Results
Changes of serum survivin levels during the SWEFOT trial
At baseline, 114 of 302 patients (38 %) were survivin-
positive (+). The survivin (+) patients were significantly
more often RF (+) and tended to have higher functional
disability by HAQ compared to survivin (−) patients
(Table 1). There were no differences in baseline disease
activity by DAS28 or any other core set clinical out-
comes. Serum survivin levels decreased significantly
from baseline over 24 months (Fig. 2). The majority of
patients (167/294, 56.8 %) remained survivin-negative
(−/−) by 3 months, and 75 patients remained survivin-
positive (+/+). Thirty-eight patients converted to nega-
tive (+/−) by 3 months and an additional 14 patients
converted to negative (+/−) by 24 months. Of the ini-
tially survivin (−) patients, 24/188 (12.8 %) became
survivin-positive (−/+) at any time point over 24 months
(Fig. 2). The clinical significance of the change in survivin
levels with respect to the core set outcomes was assessed
for the survivin (+/+), (+/−), (−/−), and (−/+) groups
(Fig. 1).
Clinical outcomes with MTX monotherapy
After 3 months of MTX treatment, there were 101 MTX
responders and 193 MTX non-responders with available
survivin status. As reported, the MTX responders had
significantly better treatment outcomes compared to
non-responders with respect to DAS28 and other clin-
ical outcomes (P < 0.001) [11, 12, 38]. Thirty-nine of 101
(38 %) MTX responders were survivin (+), and so were
Table 1 Baseline clinical characteristics of patients with early RA
enrolled into SWEFOT, divided by survivin status
Variables Survivin-positive Survivin-negative P value
n = 114 n = 188
Age (years) 56.0 (43.0, 62.25) 57.0 (44.0, 67.0) 0.332
Sex (F) 77 (68 %) 143 (76 %) 0.107
Duration 5.0 (4.0, 8.0) 5.0 (4.0, 8.75) 0.905
RF (+) 91/113 (81 %) 108/187 (58 %) <0.001
Anti-CCP (+) 71/107 (66 %) 103/183 (56 %) 0.091
Pain-VAS 60.0 (45.75, 72.0) 54.0 (39.0, 71.0) 0.269
PtGA-VAS 60.0 (39.0, 77.0) 58.0 (35.25, 74.0) 0.452
HAQ 1.25 (0.85, 1.75) 1.0 (0.75, 1.5) 0.079
TJC 8.0 (5.0, 13.0) 9.5 (6.0, 14.0) 0.134
SJC 11.0 (6.0, 14.0) 10.0 (7.0, 14.0) 0.692
ESR 35.0 (21.5, 63.0)a 34.0 (19.25, 50.0) 0.260
CRP 17.0 (9.0, 54.5)a 18.0 (9.0, 37.0) 0.628
DAS28 5.78 (5.06, 6.35)a 5.72 (5.02, 6.43) 0.751
aNumber of patients, n = 113. Serum levels of survivin >0.45 ng/mL indicate
survivin-positive patients. Statistics in the groups are presented as medians
and interquartile range (IQR). Comparisons between the groups were done by
Mann–Whitney U tests for continuous variables, and by Pearson’s χ2 tests for
frequencies. Anti-CCP, antibodies to cyclic citrullinated peptides; CRP,
C-reactive protein; DAS28, 28-joint count disease activity score; ESR, erythrocyte
sedimentation rate; F, females; HAQ, Health Assessment Questionnaire; pain-VAS,
visual analog scale for pain; PtGA-VAS, patient’s global assessment of disease
activity; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joint count;
TJC, tender joint count
Fig. 2 Changes of serum survivin levels during the SWEFOT trial.
Serum levels of survivin were measured in 302 patients enrolled in
the trial at baseline, where 114 patients were survivin-positive
(survivin > 0.45 ng/mL, dashed line), and the remaining 188 patients
were survivin-negative. In total, a decrease of survivin levels was
observed at 3, 12, and 24 months of antirheumatic treatment. The
number of samples available for the analysis is indicated at each
time point. Bolded lines indicate median levels of the survivin-
positive at baseline group (open circles) and the survivin-negative
converting to positive group at any time point over 24 months
(filled rhombi). A total of 52 (46 %) of the survivin-positive patients
converted to negative over 24 months. Comparison between the
time points was done by the Wilcoxon signed-rank test, and the
P values for the total patient cohort are indicated
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74 of 193 (38 %) MTX non-responders. Since high levels
of survivin were associated with smoking [27, 39], we
analyzed if the response to treatment was dependent on
the smoking habits of the patients. The prevalence of
ever-smokers was similar among survivin (+) (68 %) and
(−) (61 %) patients at baseline. Among the ever-smokers,
survivin (+) patients had a higher probability to be MTX
non-responders compared to survivin (−) patients (51/
71 versus 64/112, OR 1.91 (95 % CI 1.01–3.62), P =
0.045). Survivin conversion to negative (+/−) occurred
without a difference between ever- and never-smokers
(23/165 versus 13/96).
At 3 months, the survivin (+/+) MTX responders had
a higher HAQ compared to those who converted nega-
tive (+/−), indicating a delay in improvement of their
functional disability (Fig. 3a). This higher HAQ was not
directly related to the disease activity, since the survivin
(+/+) patients had no significant differences in DAS28,
pain-VAS, and PtGA-VAS at 3 months when compared
to the other survivin groups.
Among initial MTX responders who continued on
MTX monotherapy, survivin (+) patients had a higher
risk of disease reactivation (DAS28 > 3.2) at 12 months
compared to survivin (−) patients (12/36 versus 7/52,
OR 3.21 (1.12–9.24), P = 0.032). Also, survivin (+/+) pa-
tients on MTX monotherapy had significantly higher
DAS28, HAQ, and PtGA-VAS compared to the survivin
(−/−) patients (Fig. 3a). This difference was maintained
at 24 months compared to the survivin (+/−) and (−/−)
subgroups (Fig. 3a).
Clinical outcomes with combined antirheumatic
treatments
MTX non-responders were randomized to TT (n = 85)
or to anti-TNF (n = 76) treatment. At 12 months, the
TT-treated survivin (+/−) subgroup (n = 19) had better
outcomes compared to the survivin (−/+) subgroup
(n = 7) in DAS28, pain-VAS and in PtGA-VAS (Fig. 3b),
and had significantly lower DAS28 and pain-VAS com-
pared to anti-TNF-treated survivin (+/−) patients (n = 13)
(median (IQR) 2.34 (1.94, 3.56) versus 3.43 (2.82, 4.96),
P = 0.045; and 21.0 (10.0, 38.0) versus 35.0 (24.5, 59.0),
P = 0.033, respectively). Among anti-TNF-treated patients,
the survivin subgroups had no differences in core set out-
comes (Fig. 3c).
At 24 months, better clinical outcomes were found
among the survivin (+) patients at baseline ((+/+) and
(+/−), n = 14 + 19) randomized to TT compared to the
survivin (+) patients (n = 16 + 13) randomized to anti-
TNF. The TT-treated survivin (+) patients attained a sig-
nificantly lower DAS28 (2.37 (1.79, 3.27) versus 3.50
(2.05, 4.63), P = 0.020), and the estimated risk of active
disease activity (DAS28 > 3.2) was higher among the
anti-TNF-treated survivin (+) patients (55 % versus 28 %;
OR 3.15 (95 % CI 1.09–9.10), P = 0.037) (Fig. 4). Con-
sequently, the prevalence of DAS28 < 3.2 among the
TT-treated survivin (+) patients was similar to MTX
responders (72 % and 75 %, respectively). Analogously,
TT-treated survivin (+/+) patients (n = 14) had a lower
pain-VAS compared to anti-TNF-treated survivin (+/+)
patients (n = 16) (14.0 (3.75, 23.0) versus 33.0 (15.0, 66.0),
P = 0.038), and the survivin (+/−) patients treated with
anti-TNF had a high frequency of active disease compared
to the TT-treated subgroup (62 % versus 26 %, P = 0.046).
Survivin (−/−) patients showed similar responses to TT
and anti-TNF treatment and reached comparable DAS28,
HAQ, pain-VAS, and PtGA-VAS outcomes (Fig. 3b,c).
The proportion of patients with DAS > 3.2 among MTX
responders and survivin (−) at baseline ((−/−) and (−/+),
n = 51 + 1) was always lower when compared to survivin
(−) MTX non-responders (n = 83 + 13) (Fig. 4). The
survivin (−/+) patients treated with TT and anti-TNF
had similar outcomes.
Discussion
We studied the importance of serum survivin levels dur-
ing antirheumatic treatment by post hoc analysis of the
SWEFOT trial cohort. Our results confirm that patients
survivin-positive at baseline can have poor long-term
outcomes. Patients who remain positive by 3 months,
despite initially responding by DAS28, are recognized by
a risk for later disease reactivation and possess early
functional disability that deteriorates even further over
24 months. These findings support the previously re-
ported association between radiographic damage and a
considerable gain in HAQ over time despite clinical re-
mission [40]. It also may at least in part explain the obser-
vations from the BARFOT cohort indicating significantly
higher 60-month disease activity and radiographic pro-
gression in survivin-positive early RA patients [27]. Not-
ably, the survivin-positive patients within the BARFOT
and SWEFOT cohorts of early RA patients had com-
parable levels of DAS and HAQ at 24-month follow-
up despite obvious differences in therapeutic choices and
significantly higher remission rates reached by groups with
different survivin status within the SWEFOT trial.
Female gender, age, current smoking, and functional
disability as predictors of MTX response were previously
established [41]. We extend the list of predictors with
survivin measurements and show that survivin binds to-
gether as an environmental risk represented by smoking,
with clinical parameters of disease activity and functional
disability. Concerning the analysis of survivin groups, nei-
ther the presence of RF or antibodies against citrullinated
peptides, nor the combined multi-biomarker disease activ-
ity score [42] supported discrimination in the disease out-
come achieved by survivin measurements (results not
shown). Taken in concert, these observations confirm the
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Fig. 3 Core set clinical parameters in the survivin subgroups of the SWEFOT trial. At baseline, all patients were treated with methotrexate (MTX).
a At 3 months, the patients with a disease activity score (DAS28) < 3.2 proceeded on MTX monotherapy. b The patients with a DAS28 > 3.2 were
randomized to triple therapy with MTX + sulfasalazine (SSZ) + hydroxychloroquine (HCQ), c or to anti-TNF therapy (MTX + infliximab). The
intention-to-treat analysis was conducted for clinical parameters, including the DAS28, functional disability (Health Assessment Questionnaire,
HAQ), pain perception with the visual analog scale (pain-VAS), and the patient’s global assessment of disease activity (PtGA-VAS). Boxes represent
the 25th to 75th percentile of the group, and horizontal lines within the boxes indicate median values. Four groups of patients were compared:
patients positive for survivin (PP), and negative for survivin (NN) at baseline and over 24 months; patients positive for survivin at baseline who
converted negative (PN), and negative for survivin who converted positive (NP) over 24 months. Comparisons of the absolute values were done
by Mann–Whitney U tests
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independent predictive value of survivin measurements in
early RA and suggest that survivin-positive patients re-
quire initial combination treatment to avoid potentially ir-
reversible outcomes.
The other important finding of this study is related to
the choice of treatment after failure to respond ad-
equately to MTX. The primary response to MTX and
early remission remained a major predictor of long-term
clinical outcomes for patients in the SWEFOT trial, and
the combined intensive treatment for MTX non-
responders in this trial was not sufficient for achieving
the same outcomes. The importance of MTX response
has been initially reported in randomized goal-steered
treatment studies [43, 44] and repeated by observational
studies [45, 46] and a meta-analysis [47]. Our data show
that for survivin-positive patients, TT is an effective
treatment option with a rate of remission in this group
comparable to the MTX responder group. Surprisingly,
anti-TNF treatment appeared to be less successful for
survivin-positive MTX non-responders.
Several approaches to understanding the nature of
poor anti-TNF response have been proposed, where gen-
etic variations and TNF-independent mechanisms of
arthritis have been extensively explored. Despite exten-
sive candidate gene-driven and whole-genome based re-
search, presenting several loci involved in anti-TNF
treatment response, no sustainable solutions have cur-
rently been found [48–50]. In addition, attempts to iden-
tify autoantibody and cytokine profiles suggest a potential
predictive signature [42, 51, 52], although, in light of these
promising results, the practical value remains yet to be
elucidated.
The SWEFOT trial demonstrates that survivin is a
changeable serologic marker with a notable connection
to disease outcome. A decrease of serum survivin levels
is shown to be an overall consequence of antirheumatic
treatment, and serological conversion to survivin-nega-
tive occurred in about a half of the survivin-positive pa-
tients. Most of the survivin conversion was identified
after 3 months of MTX monotherapy. It was coupled
with excellent clinical outcomes and a low reactivation rate
at follow-up. In contrast, patients who gained survivin-
positivity were comprised almost solely of MTX non-
responders with poor outcomes, irrespective of treatment
modality. For the first time, survivin status and conversion
have been associated with clinical manifestations of early
RA in a pragmatic clinical setting of the broad care-based
SWEFOT trial. In the original report [11], the anti-TNF
group was shown to provide significantly better clinical re-
sponses and non-significantly different radiographic out-
comes in comparison to TT at 12 months, which was
reversed at 24 months [12]. Now, we identify a subgroup
of survivin-positive patients not responding effectively to
anti-TNF therapy. Thus, the monitoring of survivin levels
assists in prognosis and treatment decisions for patients
with early RA.
The nature of extracellular survivin release remains an
enigma. Since active extracellular transport of survivin is
described only as exosomal content [53], profound cellu-
lar disruption could be a cause of intermittent serum
levels of survivin. The poor response to anti-TNF treat-
ment observed in this study and lack of a direct correl-
ation between serum survivin and inflammatory markers,
including C-reactive protein and IL-6 [29, 33, 54], suggests
Fig. 4 Prevalence of active disease among survivin-positive or survivin-negative patients in the SWEFOT trial. The prevalence of active disease
(disease activity score, DAS28 > 3.2) among patients who were survivin-positive or survivin-negative at baseline is presented for the groups treated
with methotrexate (MTX) monotherapy and the groups randomized to triple therapy (TT) or to anti-TNF therapy. Comparisons were done by
Pearson’s χ2 or Fisher’s exact tests, and odds-based estimates (odds ratio, OR) and 95 % confidence intervals (CI) are indicated. Two patients with
no available DAS28 at 3 months were excluded from the analysis
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a TNF-independent mechanism of survivin release. Extra-
cellular survivin has been shown to be biologically active
inducing surface expression of adhesion molecules on leu-
kocytes of RA patients [55] with a potential to regulate T
cell functions and motility through a broad net of intracel-
lular effectors [56, 57]. At the preclinical stage of arthritis,
serum survivin has been associated with the release of cy-
tokines controlling the formation of Th cell subsets Th1
and Th17 [26, 58]. Inhibition of survivin in experimental
arthritis proved its intimate relation to the formation of ef-
fector T cells and to the system of matrix proteases in the
inflamed joints [54, 59]. The processes triggering and ab-
rogating survivin release in RA could therefore pave a way
to efficient therapeutic control of the disease.
Several points in the specificity of this analysis could
have influenced the results. The SWEFOT trial does not
account for patients changing treatment by adjusting
drug doses or switching to cyclosporine A for the TT
group or etanercept for the anti-TNF group due to tox-
icity. Drug cytotoxicity could be responsible for disease-
independent survivin release, although the number of
such patients was small. Also, a group of patients with
frequently changeable survivin status were excluded
from statistical analysis. The analysis does not account
for the autoantibody status within the survivin groups,
since no association between the presence of autoanti-
bodies and a decrease of survivin levels was noted after
3 months of MTX monotherapy. Combined survivin
and autoantibody analysis could have strengthened the
obtained results due to the tight coexistence of these
biomarkers in severe RA [27, 28]; however, it could have
given the opposite result due to the association of auto-
antibodies with a strong response to anti-TNF treatment
[52]. The limited final numbers of patients allocated and
followed-up within the TT- and anti-TNF-treated groups
do not permit a complete exclusion of a serendipitous
outcome. Nonetheless, the SWEFOT study was ad-
equately powered to address whether survivin could be a
predictor of response, with the utilization of robust non-
parametric statistical methods – and sensitivity analyses
of the patients who completed the study per protocol
confirmed the superior effect of TT on survivin-positive
patients. Finally, it is important to keep in mind that poor
outcomes among the groups of MTX non-responders are
not restricted to survivin status. A substantial number of
survivin-negative patients failed to respond to TT and
anti-TNF treatment for reasons yet unknown.
Conclusions
Our results indicate that the measurement of serum
survivin is useful for planning treatment strategies in pa-
tients with early RA. High levels of survivin identify pa-
tients with a worse prognosis and a risk for disease
reactivation attended by deteriorating functional disability
while on MTX monotherapy, whereas the combin-
ation of synthetic disease-modifying drugs appears to
be more effective than a biological treatment strategy
with anti-TNF.
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